Loading
A phase 2/3 trial of anlotinib in lung cancer, run by Hunan Province Tumor Hospital, now recruiting.
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer is a phase 2/3, interventional study registered as NCT04322617 by Hunan Province Tumor Hospital, with a registry enrolment figure of 1200 participants, started 2020-03-24 and due to reach its primary completion in 2028-03-24. Interventions recorded: Anlotinib plus the same Immune Checkpoint Inhibitors.; Anlotinib plus the new Immune Checkpoint Inhibitors.; Anlotinib. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Progression free survival time (PFS). Lung eligibility wording from the registry: "Histopathology or cytology confirmed lung cancer". Sites: China. No results are recorded here; the registry entry is the source.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.